ATE355527T1 - Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit - Google Patents

Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit

Info

Publication number
ATE355527T1
ATE355527T1 AT00929471T AT00929471T ATE355527T1 AT E355527 T1 ATE355527 T1 AT E355527T1 AT 00929471 T AT00929471 T AT 00929471T AT 00929471 T AT00929471 T AT 00929471T AT E355527 T1 ATE355527 T1 AT E355527T1
Authority
AT
Austria
Prior art keywords
disease
activity
level
subject
diagnosing
Prior art date
Application number
AT00929471T
Other languages
English (en)
Inventor
Roger Nitsch
Christoph Hock
Uwe Otten
Original Assignee
Evotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99108722A external-priority patent/EP1050757A1/de
Application filed by Evotec Ag filed Critical Evotec Ag
Application granted granted Critical
Publication of ATE355527T1 publication Critical patent/ATE355527T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/48—Nerve growth factor [NGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00929471T 1999-05-03 2000-05-02 Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit ATE355527T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99108722A EP1050757A1 (de) 1999-05-03 1999-05-03 Methoden zur Diagnostizierung oder zur Behandlung von neuropsychiatrischen Erkrankungen, die auf erhöhten Nervenwachstumsfaktor (NGF)-Spiegel basiert sind
EP99120211 1999-10-09

Publications (1)

Publication Number Publication Date
ATE355527T1 true ATE355527T1 (de) 2006-03-15

Family

ID=26152988

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00929471T ATE355527T1 (de) 1999-05-03 2000-05-02 Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit

Country Status (6)

Country Link
US (1) US20050130233A1 (de)
EP (1) EP1173769B1 (de)
AT (1) ATE355527T1 (de)
AU (1) AU4753900A (de)
DE (1) DE60033646T2 (de)
WO (1) WO2000067033A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1534856A2 (de) * 2002-09-02 2005-06-01 EVOTEC Neurosciences GmbH Diagnostische und therapeutische verwendung von thbp im kontext neurodegenerativer erkrankungen
EP1633786A4 (de) * 2002-10-09 2007-07-25 Rinat Neuroscience Corp Verfahren zur behandlung der alzheimer-krankheit mit antikörpern gegen amyloid-beta-peptid und zusammensetzungen daraus
GEP20115195B (en) 2004-07-30 2011-04-11 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and use thereof
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
JP2007151680A (ja) * 2005-12-01 2007-06-21 Hi-Lex Corporation スカフォールド材料

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1243281B (it) * 1990-06-12 1994-05-26 Fidia Spa Metodo per la determinazione quantitativa e qualitativa di polipeptidiin liquidi proteici
WO1994019461A1 (en) * 1993-02-17 1994-09-01 Cephalon, Inc. METHOD FOR IDENTIFYING COMPOUNDS THAT INDUCE AN INCREASED LEVEL OF THE NERVE GROWTH FACTOR mRNA

Also Published As

Publication number Publication date
DE60033646D1 (de) 2007-04-12
US20050130233A1 (en) 2005-06-16
EP1173769A1 (de) 2002-01-23
EP1173769B1 (de) 2007-02-28
WO2000067033A1 (en) 2000-11-09
DE60033646T2 (de) 2007-11-29
AU4753900A (en) 2000-11-17

Similar Documents

Publication Publication Date Title
ATE462710T1 (de) Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert
DE60233485D1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
ATE419390T1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
ATE502119T1 (de) Verfahren zur bewertung pathologischer krankheitszustände unter verwendung extrazellulärer rna
WO2004046729A3 (en) Bodily fluid markers of tissue hypoxia
ATE488251T1 (de) Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
DE60016178D1 (de) Verfahren zur diagnose und zur charakterisierung von schlaganfall
DE69534802D1 (de) VERWENDUNG VON IN NEURITEN LOKALISIERTEN mRNAs ZUR MEDIZINISCHEN DIAGNOSE UND THERAPIE
ATE283487T1 (de) Verfahren zur diagnose oder prognose von altersbedingter maculadegeneration
DE69510336D1 (de) Verfahren zur diagnose von praeklampsie
ATE286253T1 (de) Methoden zur diagnose oder prognose der alzheimerschen krankheit
DE60033646D1 (de) Methoden zur diagnostizierung oder zur behandlung der alzheimer-krankheit
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
ATE126599T1 (de) Verfahren zur bestimmung von anti-rns- antikörpern.
ATE415632T1 (de) Verfahren zur diagnose und behandlung von morbus crohn
DE60234958D1 (de) Psoriasin-expression durch brustepithelzellen
DE60038614D1 (de) Verfahren zur diagnose von synovialen oder osteoartikulären erkrankungen
ATE449964T1 (de) DIAGNOSTISCHE VERWENDUNG VON ßENSADIN-0477ß FÜR NEURODEGENERATIVE ERKRANKUNGEN
ATE546547T1 (de) Diagnose der chronischen abstossung
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
EP1363528A4 (de) Verfahren zur diagnose und behandlung von herzerkrankungen
DE60031518D1 (de) Methode zur Diagnostizierung, Prognose oder Evaluation von Behandlung der Depressionen, basiert auf erhöhte Neurotrophin Concentrationen in zerebrospinale Flüssigkeit.
ATE401576T1 (de) Verwendung eines zum kern beschränkten protein für die diagnose und therapie von alzheimer- krankheit und relatierte neurodegeneratiefe störungen
FI951778A0 (fi) Menetelmä allergian toteamiseksi
RU2188429C2 (ru) Способ прогнозирования обострений вирусных гепатитов

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties